Formoterol Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Bronchospasm Prophylaxis

To prevent exercise induced bronchospasm:

12 mcg (1 inhalation) of powder at least 15 minutes before exercise as needed. Additional doses should not be taken for 12 hours.

Usual Adult Dose for Asthma - Maintenance

12 mcg (1 inhalation) of powder every 12 hours. Total daily dose should not exceed 24 mcg.

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

formoterol 12 mcg inhalation capsule:
12 mcg (1 inhalation) of powder every 12 hours. Total daily dose should not exceed 24 mcg.

formoterol 20 mcg/2 mL inhalation solution:
one 20 microgram/2 mL vial via jet nebulizer with a facemask or mouthpiece every 12 hours.

Usual Pediatric Dose for Bronchospasm Prophylaxis

To prevent exercise induced bronchospasm:
5 years or older: 12 mcg (1 inhalation) of powder at least 15 minutes before exercise as needed. Additional doses should not be taken for 12 hours.

Usual Pediatric Dose for Asthma - Maintenance

5 years or older:
12 mcg (1 inhalation) of powder every 12 hours. Total daily dose should not exceed 24 mcg.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

For long-term asthma control, long-acting beta 2- agonists should be used in combination with inhaled corticosteroids and not as monotherapy.

Because long-acting beta 2- agonists (LABAs) may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise induced bronchospasm is discouraged by the NIH Asthma Guidelines (NIH, 2007).

Dialysis

Data not available

Other Comments

Formoterol is not intended for the treatment of acute bronchospasm. Patients should be provided with a short-acting beta-2 agonist for the treatment of acute symptoms.

The regular use of beta-2 agonists has been associated with a mild increase in airway responsiveness, a decrease in the bronchoprotective effect, and a deterioration in disease control. Patients requiring more than four inhalations of an additional short-acting beta-2 agonist daily should be reevaluated by a physician.

Hide
(web4)